|
assessing the efficacy of a multi-strain probiotics in combination with standard care in mild to moderate ulcerative colitis
|
01-10-202330-09-2025
|
Penyelidik Bersama
|
|
-
|
01-08-202331-12-2024
|
Ahli Kumpulan
|
|
the effect of palm tocotrienol rich fraction on alcoholic fatty liver disease (afld): a phase ii clinical trial
|
11-11-202110-11-2024
|
Penyelidik Bersama
|
|
the effect of palm tocotrienol rich fraction on alcoholic fatty liver disease (afld): a phase ii clinical trial
|
11-11-202110-11-2024
|
Penyelidik Bersama
|
|
a phase 3, multicenter, open-label extension study to evaluate the long term efficacyand safety of mirikizumab in patients with moderately to severely active ulcerativecolitis(protocol no.: i6t-mc-amap)
|
13-10-201912-10-2024
|
Penyelidik Bersama
|
|
combined phase 3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active crohn`s disease
|
16-03-201715-07-2024
|
Penyelidik Bersama
|
|
tocotrienol as a treatment for non-alcoholic fatty liver disease: a randomized controlled trial
|
10-04-202030-06-2024
|
Penyelidik Bersama
|
|
tocotrienol as a treatment for non-alcoholic fatty liver disease: a randomized controlled trial
|
10-04-202030-06-2024
|
Penyelidik Bersama
|
|
m14-675: a multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active ulcerative colitis
|
13-06-201912-06-2024
|
Penyelidik Bersama
|
|
prevalence of metabolic dysfunction-associated fatty liver (mafld) among nurses in a single tertiary care centre and the role of intermittent fasting in improving hepatic steatosis.
|
02-05-202301-05-2024
|
Penyelidik Bersama
|
|
a phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study of mirikizumab in conventional-failed and biologic-failed patients with moderately to severely active ulcerative colitis(protocol no: 16t-mc-aman)
|
27-12-201826-10-2023
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of risankizumab in subjects with moderately to severely active crohn`s disease
|
14-09-201713-07-2023
|
Penyelidik Bersama
|
|
elucidating the effects of methotrexate therapy on serum cytokeratin-18 levels in rheumatology
|
22-04-202121-04-2023
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo controlled maintenance and long term extension study of the efficacy and safety of upadacitinib (abt-494) in subjects with crohn’s disease who completed the m14-431 or m14-433 studies
|
12-04-201811-04-2023
|
Penyelidik Bersama
|
|
a phase 3, multicenter, randomized, double-blind, parallel-arm, placebo-controlled maintenance study of mirikizumab in patients with moderately to severely active ulcerative colitis.protocol no: 16t-mc-ambg
|
27-12-201826-02-2023
|
Penyelidik Bersama
|
|
a phase 3 multicenter, open-label extension (ole) study to evaluate the long-term safety and efficacy of abt-494 in subjects with ulcerative colitis (uc)
|
16-02-201715-02-2023
|
Penyelidik Bersama
|
|
a long-term extension study to evaluate the safety of filgotinib in subjects with ulcerative colitis
|
13-04-201712-12-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled 52-week maintenance and an open-label extension study of the efficacy and safety of risankizumab in subjects with crohn`s disease who responded to induction treatment in m16-006 or m15-991
|
26-10-201725-11-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study to assess the efficacy and safety of risankizumab in subjects with moderately to severely active crohn`s disease who failed prior biologic treatment
|
14-09-201713-10-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active crohn`s disease who have inadequately responded to or are intolerant to biologi
|
12-04-201811-04-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active crohn’s disease who have inadequately responded to or are intolerant to
|
12-04-201811-04-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of abt-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis
|
16-02-201715-02-2022
|
Penyelidik Bersama
|
|
combined phase 2b/3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active ulcerative colitis
|
13-04-201712-02-2022
|
Penyelidik Bersama
|
|
phase iii, randomized, double-blind, double-dummy, placebo-controlled, multicenter study to evaluate the efficacy (induction of remission) and safety of etrolizumab compared with adalimuman and placebo in patients with moderate to severe ulcerative coliti
|
26-02-201525-12-2021
|
Penyelidik Bersama
|
|
the effect of probiotic as an adjunct treatment for helicobacter pylori infection in adult
|
24-12-202023-12-2021
|
Penyelidik Bersama
|
|
effect of low-fodmap diet on clinical and histopathological outcomes of patients with functional dyspepsia
|
12-11-202011-11-2021
|
Ketua Projek
|
|
a study of incidence and agreement between clinical and histological features of barrett esophagus
|
14-05-202013-09-2021
|
Penyelidik Bersama
|